Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 28Terminated 5Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Advanced Cancers 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Interventional × ridaforolimus × Clear all
NCT01212627 2021-02-16

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Brown University

Phase 1 Terminated
12 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01431534 2019-03-01

MK-8669-056

Merck Sharp & Dohme LLC

Phase 1 Terminated
20 enrolled 10 charts
Other solid neoplasm

Solid Tumors

NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated
7 enrolled 13 charts

Advanced Cancers

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Merck Sharp & Dohme LLC

Phase 1 Terminated
47 enrolled 12 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00818675 2015-01-21

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Merck Sharp & Dohme LLC

Phase 2 Terminated
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡